JRCT ID: jRCT2080221295
Registered date:02/11/2010
Therapeutic use of Z-521
Basic Information
| Recruitment status | |
|---|---|
| Health condition(s) or Problem(s) studied | primary hypophosphatemic rickets |
| Date of first enrollment | 02/11/2010 |
| Target sample size | 10 |
| Countries of recruitment | |
| Study type | Interventional |
| Intervention(s) | investigational material(s) Generic name etc : Z-521 INN of investigational material : Therapeutic category code : 322 Mineral preparations Dosage and Administration for Investigational material : 300-3000mg inorganic phosphorus is orally administered in 3 or 4 times per day |
Outcome(s)
| Primary Outcome | serum ALP ( alkaline phosphatase ) level serum phosphate level |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | >= 1age old |
|---|---|
| Age maximum | <= 14age old |
| Gender | Both |
| Include criteria | subjects diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results |
| Exclude criteria | subjects with hyperparathyroidism |
Related Information
| Primary Sponsor | Zeria Pharmaceutical Co., Ltd. |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) | JapicCTI-101332 |
Contact
| Public contact | |
| Name | |
| Address | 03-5644-7053 |
| Telephone | |
| Affiliation | Zeria Pharmaceutical Co., Ltd. |
| Scientific contact | |
| Name | |
| Address | |
| Telephone | |
| Affiliation | |